Bova Scholars
Welcome to our Bova Scholars hub. Here you will find all our CPD – all free, and all from experts in their field. We have a passion for innovation, and this not only extends to the products we deliver, but to the education and CPD we create. We aim to provide you with the latest research, thinking and treatment options with easily accessible blogs, podcasts and webinars. So, whether you’re a reader, a listener or a watcher, we have you covered.
-
-
Upcoming
Communicating with caregivers about FIP
By the end of this webinar, participants should be able to: Explain key information caregivers need immediately following an FIP diagnosis Reduce caregiver stress, build trust, and help caregivers navigate online communities while avoiding misleading or exploitative recommendations Respond effectively to common caregiver questions and concerns during FIP treatment Demonstrate practical strategies for administering medication to improve caregiver treatment compliance Apply practical tools and resources to support caregivers through the treatment process
-
Upcoming
-
Upcoming
-
Upcoming
Beyond FIP: the role of coronavirus in multi-cat households and catteries
By the end of this lecture, participants will be able to: Describe the epidemiology, transmission, and shedding patterns of feline coronavirus in multi-cat environments. Interpret FCoV diagnostic tests and understand their strengths and limitations in clinical practice. Identify evidence-based strategies to reduce FCoV transmission in multi-cat households and breeding catteries. Develop practical recommendations for breeders and shelters regarding infection control, kitten management, and FIP risk reduction.
-
Upcoming
Available medications: experiences and controversies
By the end of this webinar, participants should be able to: Compare compounded antiviral drugs to unlicensed “black market” formulations, and explain the risks of unlicensed products Identify the legal status of compounded antivirals in my country, and know where to go to find updates Explain factors contributing to the ongoing use of unlicensed formulations globally Understand the importance of veterinary continuing education on this topic, and where to direct my colleagues who are not yet informed about FIP therapy Recognize the critical importance of stocking antiviral drugs in my hospital (where legally allowable)
-
Upcoming
My most challenging FIP cases and how I treated them (live panel)
By the end of this lecture, participants will be able to: 1. Recognize atypical and complicated presentations of feline infectious peritonitis, including concurrent sepsis, IMHA and infectious co-morbidities. 2. Recognize complicated FIP cases that may not look like FIP on the first sight 3. Develop diagnostic plans to distinguish FIP progression from secondary complications or concurrent diseases. 4. Formulate evidence-informed treatment strategies that integrate antiviral therapy with management of immune-mediated, and infectious complications.
-
Upcoming
‘Long-FIP’: residual effects and latest research
By the end of this webinar, participants should be able to: Describe the currently recognised long-term clinical, laboratory, and imaging findings in cats following successful antiviral treatment of FIP. Differentiate residual post-FIP abnormalities from true FIP relapse and recognise that persistent or newly developing abnormalities after successful treatment do not necessarily indicate FIP. Recognise newly emerging diseases in FIP survivors, including lymphoma, and incorporate appropriate differential diagnoses when cats develop clinical signs following successful FIP treatment. Develop a rational approach to long-term follow-up of FIP survivors, including appropriate investigation of persistent or new abnormalities.
-
Upcoming
-
Upcoming
Relapse or re-emergence: treating cases where the signs return
By the end of this lecture, participants will be able to: Understand current working definitions including treatment failure and re-emergent FIP Explain why “re-emergent FIP” is preferred over relapse vs reinfection in most clinical settings Understand the pros and cons of repeating re-treatment too soon Describe practical retreatment approaches based on prior response and current disease presentation
-
Upcoming
Molnupiravir and EIDD-1931: personal experiences and recommendations
By the end of this lecture, participants will be able to: Describe the pharmacology and mechanisms of action of molnupiravir (EIDD-2801) and EIDD-1931 in the treatment of feline infectious peritonitis. Apply evidence-based dosing protocols and monitoring strategies for cats with effusive, non-effusive, neurological, and ocular FIP. Recognize expected treatment responses, laboratory changes, adverse effects, and indications for dose adjustments or retreatment. Develop practical treatment plans based on published evidence and real-world clinical experience to maximize treatment success and manage challenging or relapsing cases.
-
Upcoming
Treatment duration: evidence for shorter courses and when they need longer
Historically, a 84-day (12-week) course of antiviral treatment with GS-441524 was the standard approach for treating cats with feline infectious peritonitis (FIP), largely based on the protocols used in early GS-441524 studies rather than on evidence establishing 84 days as the minimum duration required for cure. Early studies demonstrated excellent efficacy with prolonged treatment, but relapses—particularly neurological relapses—were observed in some cats and contributed to a cautious approach to treatment duration.More recent evidence challenges the need for routine 84-day therapy.
-
Upcoming
GS-441524 and remdesivir: where we started and what we have learnt
Summarise the evidence supporting GS-441524 and remdesivir as effective treatments for FIP. Explain current consensus recommendations (ISCAID treatment guideline) regarding first-line antiviral therapy for FIP.
-
Upcoming
Using oral remdesivir in New Zealand
This presentation will review the current evidence supporting antiviral treatment of FIP with oral remdesivir. This medication has been less commonly used internationally but in some countries such as New Zealand it has been the most available option so has been well utilised. The pharmacology of remdesivir and its relationship to GS-441524 will be discussed, including recent pharmacokinetic studies that have improved our understanding of drug absorption, metabolism and systemic exposure following oral administration. Emerging clinical data comparing oral remdesivir with GS-441524 in cats with naturally occurring FIP will be examined.
-
Upcoming
Do we need to worry about resistance?
Describe the broad biological and evolutionary processes by which antiviral resistance can emerge in RNA viruses. Outline mechanisms of antiviral resistance development in coronaviruses with nucleoside analogues, drawing on evidence from human COVID-19 literature. Describe the implications of subtherapeutic dosing, prolonged treatment, and immunocompromised states for driving antiviral resistance in feline coronaviruses.
-
Upcoming
Complications of FIP: IMHA, sepsis and myocarditis
This lecture will review the imaging findings associated with FIP across multiple modalities, including thoracic radiography, abdominal ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Participants will learn the most common thoracic and abdominal abnormalities reported in the literature and observed in clinical practice, including pleural and peritoneal effusions, lymphadenomegaly, hepatic, gastrointestinal and renal lesions.
-
Upcoming
Imaging findings in cats with FIP: from POCUS to MRI
This lecture will review the imaging findings associated with FIP across multiple modalities, including thoracic radiography, abdominal ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Participants will learn the most common thoracic and abdominal abnormalities reported in the literature and observed in clinical practice, including pleural and peritoneal effusions, lymphadenomegaly, hepatic, gastrointestinal and renal lesions.
-
Upcoming
Diagnosing FIP in the era of treatment: which tests are most important?
This webinar will discuss the interpretation and limitations of commonly requested tests, including albumin-to-globulin ratio, acute-phase proteins, Rivalta testing, feline coronavirus serology, RT-qPCR and coronavirus mutation analysis. We will also consider when a negative result does not exclude FIP, and when a carefully monitored treatment trial is reasonable. By the end of the session, delegates should be able to select diagnostic tests based on the individual cat’s presentation, interpret results within the context of disease probability and make timely, evidence-based decisions about initiating antiviral treatment.
-
Upcoming
FIP diagnostics: PCR, ICC, IHC and the evolving role of test performance in the era of machine learning
Determine when FCoV PCR, ICC, and IHC should be considered based on clinical presentation and sample accessibility Interpret the sensitivity and specificity of PCR, ICC, and IHC in the literature, and explain how these are influenced by sample type and disease presentation Select appropriate sample types for each diagnostic modality and recognise key practical limitations, including effects of sample handling, transport, and storage Evaluate how the availability of effective treatment has shifted diagnostic priorities, particularly the balance between maximising specificity versus avoiding false negatives and diagnostic delay Recognise the emerging role of data-driven approaches (including machine learning) in FIP diagnostics, and their potential to influence future interpretation and clinical decision-making
-
Upcoming
The Cyprus experience: FCoV-23 and what happened next
A brief reminder of the FCoV-23 outbreak in 2023 in Cyprus The methodology of epidemiological monitoring of the FCoV23 in Cyprus The genetics behind the outbreakNew clinical information regarding FCoV-23 How is the situation now across the island? First prospective data regarding FCoV-23 FIP treatment response First prospective data regarding the epidemiological data in the shelters and monitoring of the FIP in Cyprus
-
Upcoming
-
Upcoming
Pathogenesis of FIP: understanding the basics
Understand the basic structure of the feline coronavirus (FCoV) genome and the important differences between serotype 1 and serotype 2 FCoV. Understand the basic pathological processes underpinning FCoV infection and feline infectious peritonitis (FIP) Appreciate how the features of the FCoV genome, replication, and pathogenesis impact on diagnostics.
-
Upcoming
FIP – Facts, Insights & Progress
Whether you’re newly qualified or a seasoned feline specialist, this is CPD built for every stage of the FIP learning curve — brought to you by the clinicians and researchers shaping how the profession understands and treats this disease today.
-
On-Demand
Clinical approach to the EGGD case (2026)
A practical veterinary guide to diagnosing and managing equine glandular gastric disease, including co-morbidities, treatment choices and expected early response.
-
On-Demand
Where does doxepin fit into managing pruritic skin disease in the horse? (2026)
A practical veterinary guide to doxepin in the pruritic horse, including mechanism, self-trauma, steroid-sparing use, diagnostics and reassessment.
Veterinary Webinars
Free online webinars for vets and nurses to gain continued professional development (CPD). We work with a range of key opinion leaders to bring you up-to-date information on a variety of disease areas.
Veterinary Podcasts
Learn on the go with our podcasts. Delivered by key opinion leaders for the latest thinking on a variety of disease areas.
How-To Videos
Easy-to-follow videos for using our products – ideal to share with pet owners.
Veterinary Useful Resources
Invaluable resources tailored to elevate your expertise in veterinary practice. Explore our comprehensive toolkit here.